Research programme: nanoparticle therapeutics - Midatech

Drug Profile

Research programme: nanoparticle therapeutics - Midatech

Alternative Names: Gold nanoparticle encapsulated therapeutics - Midatech; Immuno-oncology TAM MTR- Midatech; Immuno-oncology vaccine MTR - Midatech; MTECHR 01; MTECHT 02; MTECHT 03; MTECHV 02; Nanoparticle bound amoxicillin - Midatech

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Midatech
  • Developer Dana-Farber Cancer Institute; Midatech
  • Class Cancer vaccines; Conjugate-vaccines; Viral vaccines
  • Mechanism of Action Cell wall inhibitors; Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Glioblastoma
  • No development reported Bacterial infections; Cancer; Viral infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top